Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode. Jartti, T., Nieminen, R., Vuorinen, T., Lehtinen, P., Vahlberg, T., Gern, J., Camargo, C. A., & Ruuskanen, O. The Journal of Allergy and Clinical Immunology, 135(3):691–698.e9, March, 2015. doi abstract bibtex BACKGROUND: Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease. OBJECTIVE: We sought to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children. METHODS: After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load. RESULTS: Seventy-four patients completed the study (mean age, 13 months; 28% atopic). Long-term outcomes did not differ between groups (all P ≥ .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P \textless .05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P \textless .05). CONCLUSIONS: Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.
@article{jartti_short-_2015,
title = {Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode},
volume = {135},
issn = {1097-6825},
doi = {10.1016/j.jaci.2014.07.001},
abstract = {BACKGROUND: Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease.
OBJECTIVE: We sought to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children.
METHODS: After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load.
RESULTS: Seventy-four patients completed the study (mean age, 13 months; 28\% atopic). Long-term outcomes did not differ between groups (all P ≥ .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P {\textless} .05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P {\textless} .05).
CONCLUSIONS: Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.},
language = {eng},
number = {3},
journal = {The Journal of Allergy and Clinical Immunology},
author = {Jartti, Tuomas and Nieminen, Riitta and Vuorinen, Tytti and Lehtinen, Pasi and Vahlberg, Tero and Gern, James and Camargo, Carlos A. and Ruuskanen, Olli},
month = mar,
year = {2015},
pmid = {25129681},
pages = {691--698.e9},
}
Downloads: 0
{"_id":"e6cAy9QaNQyFwFCM7","bibbaseid":"jartti-nieminen-vuorinen-lehtinen-vahlberg-gern-camargo-ruuskanen-shortandlongtermefficacyofprednisoloneforfirstacuterhinovirusinducedwheezingepisode-2015","author_short":["Jartti, T.","Nieminen, R.","Vuorinen, T.","Lehtinen, P.","Vahlberg, T.","Gern, J.","Camargo, C. A.","Ruuskanen, O."],"bibdata":{"bibtype":"article","type":"article","title":"Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode","volume":"135","issn":"1097-6825","doi":"10.1016/j.jaci.2014.07.001","abstract":"BACKGROUND: Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease. OBJECTIVE: We sought to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children. METHODS: After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load. RESULTS: Seventy-four patients completed the study (mean age, 13 months; 28% atopic). Long-term outcomes did not differ between groups (all P ≥ .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P \\textless .05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P \\textless .05). CONCLUSIONS: Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.","language":"eng","number":"3","journal":"The Journal of Allergy and Clinical Immunology","author":[{"propositions":[],"lastnames":["Jartti"],"firstnames":["Tuomas"],"suffixes":[]},{"propositions":[],"lastnames":["Nieminen"],"firstnames":["Riitta"],"suffixes":[]},{"propositions":[],"lastnames":["Vuorinen"],"firstnames":["Tytti"],"suffixes":[]},{"propositions":[],"lastnames":["Lehtinen"],"firstnames":["Pasi"],"suffixes":[]},{"propositions":[],"lastnames":["Vahlberg"],"firstnames":["Tero"],"suffixes":[]},{"propositions":[],"lastnames":["Gern"],"firstnames":["James"],"suffixes":[]},{"propositions":[],"lastnames":["Camargo"],"firstnames":["Carlos","A."],"suffixes":[]},{"propositions":[],"lastnames":["Ruuskanen"],"firstnames":["Olli"],"suffixes":[]}],"month":"March","year":"2015","pmid":"25129681","pages":"691–698.e9","bibtex":"@article{jartti_short-_2015,\n\ttitle = {Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode},\n\tvolume = {135},\n\tissn = {1097-6825},\n\tdoi = {10.1016/j.jaci.2014.07.001},\n\tabstract = {BACKGROUND: Rhinovirus-induced wheezing is an important risk factor for recurrent wheezing. There are no randomized controlled trials on the effect of systemic corticosteroids in patients with this disease.\nOBJECTIVE: We sought to study the short- and long-term effects of prednisolone treatment of the first acute, moderate-to-severe, rhinovirus-induced wheezing episode in young children.\nMETHODS: After confirming rhinovirus from nasopharyngeal aspirate by using PCR, 79 children with a first wheezing episode at age 3 to 23 months were randomized to receive oral prednisolone (first dose of 2 mg/kg, followed by 2 mg/kg/d in 2 divided doses for 3 days) or placebo. The trial was double blind throughout the 12-month follow-up. The primary outcomes were long term: new physician-confirmed wheezing episode within 2 months, number of physician-confirmed wheezing episodes within 12 months, and initiation of regular controller medication for asthma symptoms within 12 months. The primary interaction analysis examined rhinovirus load.\nRESULTS: Seventy-four patients completed the study (mean age, 13 months; 28\\% atopic). Long-term outcomes did not differ between groups (all P ≥ .30). For short-term outcomes, the prednisolone group had less cough, rhinitis, noisy breathing, severe breathing difficulties, and nocturnal respiratory symptoms at home within 2 weeks (all P {\\textless} .05). The 25 children with greater than 7000 rhinovirus copies/mL (most sensitive cutoff) benefitted from prednisolone in terms of less risk of physician-confirmed recurrence within 2 and 12 months compared with placebo (both P {\\textless} .05).\nCONCLUSIONS: Prednisolone cannot be routinely recommended for all young children experiencing their first acute, moderate-to-severe, rhinovirus-induced wheezing episode. Prednisolone might be beneficial in a subgroup of children with high viral loads.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {The Journal of Allergy and Clinical Immunology},\n\tauthor = {Jartti, Tuomas and Nieminen, Riitta and Vuorinen, Tytti and Lehtinen, Pasi and Vahlberg, Tero and Gern, James and Camargo, Carlos A. and Ruuskanen, Olli},\n\tmonth = mar,\n\tyear = {2015},\n\tpmid = {25129681},\n\tpages = {691--698.e9},\n}\n\n","author_short":["Jartti, T.","Nieminen, R.","Vuorinen, T.","Lehtinen, P.","Vahlberg, T.","Gern, J.","Camargo, C. A.","Ruuskanen, O."],"key":"jartti_short-_2015","id":"jartti_short-_2015","bibbaseid":"jartti-nieminen-vuorinen-lehtinen-vahlberg-gern-camargo-ruuskanen-shortandlongtermefficacyofprednisoloneforfirstacuterhinovirusinducedwheezingepisode-2015","role":"author","urls":{},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["short","long","term","efficacy","prednisolone","first","acute","rhinovirus","induced","wheezing","episode","jartti","nieminen","vuorinen","lehtinen","vahlberg","gern","camargo","ruuskanen"],"title":"Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode","year":2015}